Findings

What do systematic reviews say?

87 questions · 90 findings · 34 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 18 · 20%GRADE not reported 11 · 12.2%Very low 12 · 13.3%Low 20 · 22.2%Moderate 14 · 15.6%High 15 · 16.7%

Intervention not reported

Perinatal mortality · Pregnant women

The intervention showed no clear difference in perinatal mortality (low certainty).

1 finding from 1 review

Vitamin A supplementation during pregnancy for maternal and newborn outcomes 2015 · Cochrane Headline outcomes only
RR 0.51 [0.1, 2.69]
1 study · 179 participants
Low

Low molecular weight heparin vs vitamin K antagonist secondary prophylaxis

All‐cause mortality (main analysis ‐ active cancer) · patients with cancer with venous thromboembolism

Low molecular weight heparin secondary prophylaxis showed no clear difference in all‐cause mortality (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
RR 0.99 [0.88, 1.12]
4 studies · 1712 participants
Low

Direct thrombin inhibitors vs low molecular weight heparin

All‐cause Mortality events · patients with prevention of venous thromboembolism following total hip or knee replacement

Direct thrombin inhibitors probably leads to higher all‐cause Mortality events compared with low molecular weight heparins (moderate certainty).

1 finding from 1 review

Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous… 2010 · Cochrane Headline outcomes only
OR 2.06 [1.1, 3.87]
11 studies · 22065 participants
Moderate

Intervention not reported

All‐cause mortality: longest · infants 1 to 6 months of age

The intervention showed no clear difference in all‐cause mortality: longest (moderate certainty).

1 finding from 1 review

Vitamin A supplementation for the prevention of morbidity and mortality in infants one to six months of age 2016 · Cochrane Headline outcomes only
RR 1.05 [0.89, 1.25]
9 studies · 21339 participants
Moderate

Intervention not reported

Pneumonia‐specific mortality · children with measles

The intervention showed no clear difference in pneumonia‐specific mortality (moderate certainty).

1 finding from 1 review

Vitamin A for treating measles in children 2005 · Cochrane Headline outcomes only
RR 0.57 [0.24, 1.37]
4 studies · 723 participants
Moderate

Higher circulating 25-hydroxyvitamin D (25(OH)D) concentration vs Lower circulating 25-hydroxyvitamin D (25(OH)D) concentration

All cause mortality (in CKD patients) · Participants in observational studies

The meta-analysis of observational studies reported a RR of 0.88 (95% CI 0.81 to 0.93) for higher versus lower circulating vitamin D concentration.

1 finding from 1 review

Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational… 2014 All outcomes
RR 0.86 [0.81, 0.92]
10 studies · 6853 participants
GRADE not reported

Low molecular weight heparin vs vitamin K antagonist (VKA)

Mortality (treatment duration 3 months) · patients with symptomatic VTE requiring long term treatment (3 months) for symptomatic VTE

LMWH showed no clear difference in mortality (treatment duration 3 months) compared with VKA (moderate certainty).

1 finding from 1 review

Vitamin K antagonists versus low‐molecular‐weight heparin for the long term treatment of symptomatic venous… 2017 · Cochrane Headline outcomes only
Peto OR 1.08 [0.75, 1.56]
16 studies · 3299 participants
Moderate